ERT Celebrates TET Milestone
ERT (Philadelphia, PA) is celebrating what it describes as a significant milestone: The completion of its 150th Thorough QT clinical trial (TET).
“The TET study plays a crucial role in the development of a new pharmaceutical product," said John Blakeley, executive vice president of ERT, in a company press release. "We are very excited to have supported the industry to help improve the cardiac safety of new drugs coming to market."
With the advent of the ICH E14 Guidance in 2005, a TET has become a necessary part of the trials process for most drugs that require rigorous and robust electrocardiographic testing (ECG).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
